Hims & Hers Health Inc’s filing revealed that its Chief Financial Officer Okupe Oluyemi unloaded Company’s shares for reported $0.31 million on Jan 05 ’26. In the deal valued at $33.79 per share,9,070 shares were sold. As a result of this transaction, Okupe Oluyemi now holds 91,617 shares worth roughly $2.95 million.
Then, Okupe Oluyemi sold 23,090 shares, generating $824,710 in total proceeds. Upon selling the shares at $35.72, the Chief Financial Officer now owns 94,333 shares.
Before that, Oluyemi Okupe bought 32,160 shares. Hims & Hers Health Inc shares valued at $1,127,208 were divested by the Officer at a price of $35.05 per share.
Evercore ISI initiated its Hims & Hers Health Inc [HIMS] rating to an In-line in a research note published on January 12, 2026; the price target was $33. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in early December with a ‘”an Overweight”‘ rating. KeyBanc Capital Markets began covering HIMS with “Sector weight” recommendation on October 21, 2025. Needham revised its rating on June 23, 2025. It rated HIMS as “a Hold” which previously was an “a Buy”.
Price Performance Review of HIMS
On Tuesday, Hims & Hers Health Inc [NYSE:HIMS] saw its stock fall -0.43% to $32.2. Over the last five days, the stock has lost -9.19%. Hims & Hers Health Inc shares have risen nearly 26.72% since the year began. Nevertheless, the stocks have fallen -0.83% over the past one year.
How much short interest is there in Hims & Hers Health Inc?
A steep rise in short interest was recorded in Hims & Hers Health Inc stocks on 2025-12-31, dropping by -0.23 million shares to a total of 67.1 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 67.33 million shares. There was a decline of -0.34%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 04, 2025 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $65.
